Thermo Fisher Scientific Inc (NYSE: TMO)’s stock price has plunge by 2082922relation to previous closing price of 400.21. Nevertheless, the company has seen a -0.18% plunge in its stock price over the last five trading sessions. businesswire.com reported 2025-06-24 that SAN FRANCISCO–(BUSINESS WIRE)–Xcell Biosciences (Xcellbio), a San Francisco-based instrumentation company focused on cell and gene therapy applications, today announced a strategic collaboration with Thermo Fisher Scientific Inc., the world leader in serving science, to advance research in regulatory T cells (Tregs) and tumor-infiltrating lymphocytes (TILs). While significant progress has been made in the cell therapy space leveraging Chimeric Antigen Receptor T (CAR T) cells, this collaborat.
Is It Worth Investing in Thermo Fisher Scientific Inc (NYSE: TMO) Right Now?
Thermo Fisher Scientific Inc (NYSE: TMO) has a higher price-to-earnings ratio of 23.73x compared to its average ratio, The 36-month beta value for TMO is at 0.78. Analysts have varying views on the stock, with 18 analysts rating it as a “buy,” 7 rating it as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for TMO is 376.78M, and currently, shorts hold a 1.26% of that float. The average trading volume for TMO on June 25, 2025 was 2.71M shares.
TMO’s Market Performance
TMO stock saw an increase of -0.18% in the past week, with a monthly gain of 0.97% and a quarterly increase of -22.22%. The volatility ratio for the week is 0.37%, and the volatility levels for the last 30 days are 1.54% for Thermo Fisher Scientific Inc (TMO). The simple moving average for the last 20 days is 0.35% for TMO stock, with a simple moving average of -21.50% for the last 200 days.
Analysts’ Opinion of TMO
Many brokerage firms have already submitted their reports for TMO stocks, with Bernstein repeating the rating for TMO by listing it as a “Outperform.” The predicted price for TMO in the upcoming period, according to Bernstein is $630 based on the research report published on January 10, 2025 of the current year 2025.
TMO Trading at -2.18% from the 50-Day Moving Average
After a stumble in the market that brought TMO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.60% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TMO starting from Pettiti Gianluca, who sale 400 shares at the price of $411.11 back on May 12 ’25. After this action, Pettiti Gianluca now owns 22,767 shares of Thermo Fisher Scientific Inc, valued at $164,444 using the latest closing price.
Stock Fundamentals for TMO
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.42 for the gross margin
The net margin for Thermo Fisher Scientific Inc stands at 0.15. The total capital return value is set at 0.09. Equity return is now at value 13.73, with 6.64 for asset returns.
Based on Thermo Fisher Scientific Inc (TMO), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at 0.24. The debt to equity ratio resting at 0.69. The interest coverage ratio of the stock is 5.51.
Currently, EBITDA for the company is 11.8 billion with net debt to EBITDA at 2.84. When we switch over and look at the enterprise to sales, we see a ratio of 4.26. The receivables turnover for the company is 5.07for trailing twelve months and the total asset turnover is 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.77.
Conclusion
In conclusion, Thermo Fisher Scientific Inc (TMO) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
